Search

Camran V Parast

from Pacifica, CA
Age ~60
Get Report
Also known as:
Kamran V Parast, Canran Parast
Related to:
Mahdi VatanparastRaheleh Vatanparast Zarnagh, 53Mehri Vatan ParastI Vatanparast HSheila B Clancy, 52Jafar V ParastRoghieh V Parast, 66Roghy Parast
Connected to:
Ramya Parasuram, 40Rosemary A Paraszczak, 69Justin J Parat, 41Kartik S Parate, 34Bert J Paratore, 48Elisa I Paratore, 65Gerald J Paratore, 87Joe Paratore, 55Dominic P Paratto, 39Lee Paratto, 32

Camran Parast Phones & Addresses

  • Pacifica, CA
  • 1855 Diamond St, San Diego, CA 92109
  • San Francisco, CA
  • Garwood, NJ
  • Rahway, NJ
  • San Mateo, CA
  • Poway, CA
  • 325 Farallon Ave, Pacifica, CA 94044

Work

Company: Skyline college Aug 2006 to May 2013 Position: Adjunct professor

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Maryland 1991 to 1996 Specialities: Biochemistry, Philosophy

Industries

Higher Education

Resumes

Resumes

Camran Parast Photo 1

Consultant

View page
Location:
Pacifica, CA
Industry:
Higher Education
Work:
Skyline College Aug 2006 - May 2013
Adjunct Professor
Bia's Aug 2003 - Dec 2012
Owner
Iscientist Aug 2003 - Dec 2012
Consultant
Amgen Jan 2001 - Aug 2003
Scientist
Pfizer Apr 1996 - Jan 2001
Research Scientist
Education:
University of Maryland 1991 - 1996
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy

Publications

Us Patents

Modifications Of The Vegf Receptor-2 Protein And Methods Of Use

View page
US Patent:
6753416, Jun 22, 2004
Filed:
Aug 28, 2001
Appl. No.:
09/939833
Inventors:
Michele A. McTigue - Encinitas CA
Chris Pinko - San Diego CA
Camran V. Parast - San Diego CA
Michael R. Gehring - Ramona CA
Chen-Chen Kan - Del Mare CA
Krzysztof Appelt - Poway CA
John A. Wickersham - Escondido CA
Richard E. Showalter - Lakeside CA
Barbara Mroczkowski - Encinitas CA
Jesus E. Villafranca - San Diego CA
Assignee:
Agouron Pharmaceuticals, Inc. - San Diego CA
International Classification:
C07H 2104
US Classification:
536 231, 435183, 530300, 530350
Abstract:
A 2. 4 crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), a key enzyme in angiogenesis, has been determined in an unliganded, phosphorylated state. This protein construct, contains a modified catalytic linker and has comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, and more importantly, allows complete crystallization of the protein such that it may be characterized by X-ray crystallography. The present invention further discloses the use of x-ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions.

Modifications Of The Vegf Receptor-2 Protein And Methods Of Use

View page
US Patent:
6784285, Aug 31, 2004
Filed:
Feb 18, 2000
Appl. No.:
09/506906
Inventors:
Michele A. McTigue - Encinitas CA
Chris Pinko - San Diego CA
Camran V. Parast - San Diego CA
Michael R. Gehring - Ramona CA
Chen-Chen Kan - Del Mare CA
Krzysztof Appelt - Poway CA
John A. Wickersham - Escondido CA
Richard E. Showalter - Lakeside CA
Barbara Mroczkowski - Encinitas CA
Jesus E. Villafranca - San Diego CA
Assignee:
Agouron Pharmaceuticals, Inc. - San Diego CA
International Classification:
C07K 100
US Classification:
530402, 435 71, 435183, 530350, 536 231
Abstract:
A 2. 4 crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), a key enzyme in angiogenesis, has been determined in an unliganded, phosphorylated state. This protein construct, contains a modified catalytic linker and has comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, and more importantly, allows complete crystallization of the protein such that it may be characterized by X-ray crystallography. The present invention further discloses the use of x-ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions.

Modifications Of The Vegf Receptor-2 Protein And Methods Of Use

View page
US Patent:
6794146, Sep 21, 2004
Filed:
Aug 28, 2001
Appl. No.:
09/939832
Inventors:
Michele A. McTigue - Encinitas CA
Chris Pinko - San Diego CA
Camran V. Parast - San Diego CA
Michael R. Gehring - Ramona CA
Chen-Chen Kan - Del Mare CA
Krzysztof Appelt - Poway CA
John A. Wickersham - Escondido CA
Richard E. Showalter - Lakeside CA
Barbara Mroczkowski - Encinitas CA
Jesus E. Villafranca - San Diego CA
Assignee:
Agouron Pharmaceuticals, Inc. - San Diego CA
International Classification:
G01N 3353
US Classification:
435 71, 530300, 530350, 530402, 536 231
Abstract:
A 2. 4 crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), a key enzyme in angiogenesis, has been determined in an unliganded, phosphorylated state. This protein construct, contains a modified catalytic linker and has comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, and more importantly, allows complete crystallization of the protein such that it may be characterized by X-ray crystallography. The present invention further discloses the use of ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions.

Modifications Of The Vegf Receptor-2 Protein And Methods Of Use

View page
US Patent:
6849721, Feb 1, 2005
Filed:
Aug 28, 2001
Appl. No.:
09/939754
Inventors:
Michele A. McTigue - Encinitas CA, US
Chris Pinko - San Diego CA, US
Camran V. Parast - San Diego CA, US
Michael R. Gehring - Ramona CA, US
Chen-Chen Kan - Del Mare CA, US
Krzysztof Appelt - Poway CA, US
John A. Wickersham - Escondido CA, US
Richard E. Showalter - Lakeside CA, US
Barbara Mroczkowski - Encinitas CA, US
Jesus E. Villafranca - San Diego CA, US
Assignee:
Agouron Pharmaceuticals, Inc. - San Diego CA
International Classification:
C07K 100
C12P 2106
C12N 900
A01N 4304
C07H 2102
US Classification:
530402, 435 691, 435183, 514 44, 536 231
Abstract:
A 2. 4 Å crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), a key enzyme in angiogenesis, has been determined in an unliganded, phosphorylated state. This protein construct, contains a modified catalytic linker and has comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, and more importantly, allows complete crystallization of the protein such that it may be characterized by X-ray crystallography. The present invention further discloses the use of the x-ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions.

Modifications Of The Vegf Receptor-2 Protein And Methods Of Use

View page
US Patent:
63166038, Nov 13, 2001
Filed:
Sep 7, 1999
Appl. No.:
9/390326
Inventors:
Michele A. McTigue - Encinitas CA
Chris Pinko - San Diego CA
Camran V. Parast - San Diego CA
Michael R. Gehring - Ramona CA
Chen-Chen Kan - Del Mare CA
Krzysztof Appelt - Poway CA
John A. Wickersham - Escondido CA
Richard E. Showalter - Lakeside CA
Barbara Mroczkowski - Encinitas CA
Jesus E. Villafranca - San Diego CA
Assignee:
Agouron Pharmaceuticals, Inc. - La Jolla CA
International Classification:
C07K 100
C07K 1400
C12N 900
US Classification:
530402
Abstract:
A 2. 4. ANG. crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), a key enzyme in angiogenesis, has been determined in an unliganded, phosphorylated state. This protein construct, contains a modified catalytic linker and has comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, and more importantly, allows complete crystallization of the protein such that it may be characterized by X-ray crystallography. The present invention further discloses the use of x-ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions.
Control profile
Camran V Parast from Pacifica, CA, age ~60 Get Report